These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1242657)

  • 21. Review of the application of response surface methodology in the combination therapy of cancer.
    Carter WH; Wampler GL
    Cancer Treat Rep; 1986 Jan; 70(1):133-40. PubMed ID: 3943113
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of a simple carrier molecule to enhance drug penetration of dermal layers by utilizing multivariate methods, structure property correlations, and continuous system modeling.
    Bartzatt R
    Physiol Chem Phys Med NMR; 2004; 36(1):37-53. PubMed ID: 15789972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Problems involved in the specification and interpretation of quantitative structure-activity relationships. Part 1: A modified type of structure-activity equations.
    Mager H; Barth A
    Pharmazie; 1979; 34(9):557-9. PubMed ID: 396534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Quantitative estimation of potentiating or inhibitory effects of similarly acting drugs in combination. Advantages of a dose-response curve method over the isoboles-method (author's transl)].
    Pöch G
    Arzneimittelforschung; 1981; 31(7):1135-40. PubMed ID: 7196763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative structure activity relationship of benzoxazinone derivatives as neuropeptide Y Y5 receptor antagonists.
    Deswal S; Roy N
    Eur J Med Chem; 2006 Apr; 41(4):552-7. PubMed ID: 16545499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Quantitative structure-activity relationships for biologically active sydnones].
    Franke R; Gäbler E; Oehme P
    Acta Biol Med Ger; 1974; 32(5):545-56. PubMed ID: 4849558
    [No Abstract]   [Full Text] [Related]  

  • 27. [An application of Mantel's test to the analysis of some biological assays (author's transl)].
    Scarabin PY; Moreau T; Ducimetiere P
    Rev Epidemiol Sante Publique; 1980 Oct; 28(3):373-7. PubMed ID: 7465929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mathematical model of dose-activity relationships.
    Franke R; Oehme P; Barth A
    Environ Qual Saf Suppl; 1975; 3():461-66. PubMed ID: 1063665
    [No Abstract]   [Full Text] [Related]  

  • 29. The estimation of relative potency from two parabolas in symmetric bioassays.
    Williams DA
    Biometrics; 1973 Dec; 29(4):695-700. PubMed ID: 4785234
    [No Abstract]   [Full Text] [Related]  

  • 30. [Drug sequential analysis (author's transl)].
    Xu Duan-zheng
    Yao Xue Xue Bao; 1979; 14(1):55-64. PubMed ID: 484247
    [No Abstract]   [Full Text] [Related]  

  • 31. [Evaluation of the pain-alleviating properties of a combination of analgesic and tranquilizer using multiple stepwise regression].
    Dmitriev AV; Bershadskiĭ BG
    Farmakol Toksikol; 1985; 48(3):33-6. PubMed ID: 4029377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design.
    Pérez C; Pastor M; Ortiz AR; Gago F
    J Med Chem; 1998 Mar; 41(6):836-52. PubMed ID: 9526559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A semiparametric model for regression analysis of interval-censored failure time data.
    Finkelstein DM; Wolfe RA
    Biometrics; 1985 Dec; 41(4):933-45. PubMed ID: 3830259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploration of cluster structure-activity relationship analysis in efficient high-throughput screening.
    Wang XS; Salloum GA; Chipman HA; Welch WJ; Young SS
    J Chem Inf Model; 2007; 47(3):1206-14. PubMed ID: 17480051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
    Baert B; Deconinck E; Van Gele M; Slodicka M; Stoppie P; Bodé S; Slegers G; Vander Heyden Y; Lambert J; Beetens J; De Spiegeleer B
    Bioorg Med Chem; 2007 Nov; 15(22):6943-55. PubMed ID: 17827020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pharmacodynamic model to investigate the structure-activity profile of a series of novel opioid analgesics.
    Lutz MW; Morgan PH; James MK; Feldman PL; Brackeen MF; Lahey AP; James SV; Bilotta JM; Pressley JC
    J Pharmacol Exp Ther; 1994 Nov; 271(2):795-803. PubMed ID: 7965798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small-molecule screen identifies inhibitors of a human intestinal calcium-activated chloride channel.
    De La Fuente R; Namkung W; Mills A; Verkman AS
    Mol Pharmacol; 2008 Mar; 73(3):758-68. PubMed ID: 18083779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.
    Compton DR; Rice KC; De Costa BR; Razdan RK; Melvin LS; Johnson MR; Martin BR
    J Pharmacol Exp Ther; 1993 Apr; 265(1):218-26. PubMed ID: 8474008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current problems in drug research. I. Determination of the quantitative structure-activity relationships of biosubstances: theoretical principles, accomplishments, assumptions and present state].
    Franke R; Oehme P
    Pharmazie; 1973 Aug; 28(8):489-508. PubMed ID: 4131698
    [No Abstract]   [Full Text] [Related]  

  • 40. [Feasibility and limitations of MASCA models (multivariate structure-activity analysis in combination with multivariate bioassay].
    Mager PP; Seese A
    Pharm Unserer Zeit; 1981 Jul; 10(4):97-108. PubMed ID: 7279977
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.